RECRUITING

Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Using Multiomics

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this exploratory study is understand the mechanisms of response to immunotherapy in Non-Small Cell Lung Cancer patients. The investigators are going to search for correlation between specific biological features and response to immunotherapy, and to use those associations for developing an algorithm enabling to identify patients that could benefit from the immune check inhibitor based anti cancer treatment. Patients will provide biological samples before and during their treatment, and clinical data will be collected.

Official Title

PROPHETIC Extended - Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Extended Study.

Quick Facts

Study Start:2022-11-07
Study Completion:2028-06-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05736029

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Provision of informed consent prior to any study-specific procedures.
  2. * Male or female aged at least 18 years.
  3. * ECOG PS - 0/1-2.
  1. * Any concurrent and/or other active malignancy that has required systemic treatment within 2 years of first dose of treatment.
  2. * Generalized impairment or mental incompetence that would render the patient unable to understand his/her participation in the study.

Contacts and Locations

Study Contact

Galit Yahalom, PhD
CONTACT
97248537557
galit@oncohost.com
Shani Raveh Shoval, PhD
CONTACT
97248537557
shani@oncohost.com

Principal Investigator

Ronan J Kelly, MD MBA
PRINCIPAL_INVESTIGATOR
Chief of Oncology Baylor Scott & White Health System

Study Locations (Sites)

Baylor Scott and White Research Institute
Dallas, Texas, 75204
United States

Collaborators and Investigators

Sponsor: OncoHost Ltd.

  • Ronan J Kelly, MD MBA, PRINCIPAL_INVESTIGATOR, Chief of Oncology Baylor Scott & White Health System

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-11-07
Study Completion Date2028-06-30

Study Record Updates

Study Start Date2022-11-07
Study Completion Date2028-06-30

Terms related to this study

Additional Relevant MeSH Terms

  • Non Small Cell Lung Cancer
  • Healthy